Daré Bioscience, Inc.DARENASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -95.83% | -103.52% | +173.35% | -194.36% | -94.57% |
| Gross Profit Growth | -98.29% | +0.00% | +0.00% | -194.36% | -3758.27% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | -131.11% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | -129.41% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | -129.61% | +0.00% |
| Weighted Average Shares Growth | +12.47% | +16.46% | +4.57% | +5.47% | +49.46% |
| Weighted Average Shares Diluted Growth | +12.47% | +16.46% | +4.57% | +4.66% | +49.46% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | -141.98% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | -141.71% | +0.00% |
| Receivables Growth | -54.07% | -75.77% | -92.41% | -79.15% | -28.86% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -27.92% | +3.85% | +43.08% | -45.02% | +70.27% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +2928.68% | -7.22% | +406.34% | +98.89% | -50.24% |
| R&D Expense Growth | -60.20% | -12.85% | -31.49% | -71.04% | -73.91% |
| SG&A Expenses Growth | -24.31% | -32.45% | -13.53% | -2.87% | +16.02% |